This update on German politics – approximately 5 months ahead of the federal election – focuses on the rise of the Greens; it looks at the reasons for their poll surge, examines their policy outlook and profiles their co-leader Annalena Baerbock, who may turn out to be Angela Merkel’s successor. Finally, Primary returns to the subject of the CDU’s future: are they destined to go into opposition or are coalition partners still available? And what concessions might a new agreement require?
Joe Biden has passed through the first 100 days of his presidency; he ran on promises to lead the most progressive administration since Franklin Roosevelt, implicitly with the hope of having similar popularity and influence on politics going forward. Do his moves in his first three months merit the FDR comparisons? What message will the midterms bring?
For answers, Primary spoke to the Washington Post columnist and political historian Henry Olsen.
This note continues our analysis of US Big Tech regulation and how it is evolving in 2021.
We review recent developments at multiple levels of government involving both parties. Included are presidential personnel selections, judicial opinions, new congressional plans and individual state legislation attempts. Florida is an interesting state to follow, there too there are signs that tech regulation is becoming a key differentiating issue even with nearly three years until the 2024 presidential primaries.
The rollout of multiple Covid vaccines has (for its successes) still only added to the dimensions of political drama over the pandemic. Primary was delighted to interview Prof. Justin Stebbing, a world-famous Imperial scientist and fellow of the Royal College of Physicians and Royal College of Pathologists for his insights into these virus and vaccine challenges.
The European Court of Justice is shortly expected to deliver its definitive ruling on whether gene editing of seeds (ultimately intended to form part the human food consumption chain) will remain within the current ‘precautionary’ labelling – effectively outlawing their use within the EU jurisdiction as per their original 2018 assessment. In this article, the latest in our ESG Watch series, Primary analyses the recent history and developments in gene editing, particularly so in the CRISPR era, and presents why, in spite of significant innovation, understanding and advancement in our knowledge, the technology continues to raise so much controversy and polarisation of opinion from an ethical and bio-security perspective.